News
-
6 November 2005
Subsidiaries of Baxter International Inc. and Kuros Biosurgery AG announced that they have signed an agreement under which Kuros has granted Baxter exclusive worldwide rights to develop and commercialize a portfolio of hard and soft tissue-repair products. These products will be based on Baxter’s fibrin-based biomatrix, TISSEEL® Fibrin Sealant, combined with Kuros’ proprietary biologics and associated binding technology.
-
6 October 2005
Kuros Biosurgery AG is pleased to announce that the Company has raised CHF 5.6m in additional venture capital funding, fully subscribed by the Company’s existing investors (Venture Incubator, NeoMed Management, CDC Entreprises, Genevest Consulting Group, Vinci Capital and DEFI Gestion) and some of the Company’s employees.
-
6 June 2004
Kuros Biosurgery AG is pleased to announce that it has secured an option for a second round of venture capital financing to be exercised upon the achievement of certain key short-term milestones. When exercised, the new financing will enable the Company to extend its clinical trial activities in wound healing. In addition to existing investors the round will include three new investors from Switzerland and some of the Company’s employees. Kuros hopes to meet the relevant milestone and exercise the option later this year.
-
6 November 2002
Kuros Biosurgery AG is pleased to announce the close of its first major round of venture capital financing reflecting investor confidence in the Company's technologies and strong patent portfolio. The round was led by Venture Incubator AG, a venture capital fund based in Switzerland that invests in early stage high technology firms in the alpine rim. Further investors included NeoMed from Norway and CDC IXIS Private Equity from France.
